Level Zero Health Secures $6.9M for Wearable Hormone Monitoring

Funding & Mission : Female-founded medtech startup Level Zero Health raised an oversubscribed $6.9M pre-seed round to develop a continuous hormone monitoring device , reducing reliance on invasive blood tests.

Technology & Market Impact : The device aims to create a new product category , similar to how CGMs transformed diabetes management, potentially driving innovation in personalized medicine and hormone-based treatments.

Product Development : The startup is working on a single-use wearable patch for intermittent hormone testing , targeting fertility (IVF) and testosterone therapy (TRT), with plans to seek FDA & CE approval in 2026 .

Long-Term Vision : The ultimate goal is a fully continuous hormone monitor by 2028 , capable of tracking progesterone, estrogen, and testosterone via interstitial fluid.

Investor Confidence : Backers include Redalpine, HAX (SOSV), and Entrepreneur First , with investors highlighting the device’s potential to revolutionize diagnostics .

Accuracy & Safety : The team aims for 90%+ correlation with blood tests , emphasizing that hormone tracking carries lower medical risk compared to glucose monitoring.

Business Model : Initially a B2B strategy , selling technology to healthcare networks to accelerate adoption before moving into consumer markets.

Source: TechCrunch

M.M.